Skip to main content
. Author manuscript; available in PMC: 2022 Oct 21.
Published in final edited form as: DNA Repair (Amst). 2021 Sep 1;108:103217. doi: 10.1016/j.dnarep.2021.103217

Fig. 4. RNF8 and RNF168 protect DNA ends from resection.

Fig. 4.

(A) Southern blot analysis of XbaI-digested genomic DNA from imatinib-treated Lig4−/−, Lig4−/−:53bp1−/−, Lig4−/−:Rnf8−/− or Lig4−/−:Rnf168−/− abl pre-B cells as described in Fig. 1C. Percentages of intact SEs (iSEs) in imatinib-treated samples are listed below each lane. (B, C) Western blot analyses of whole cell lysates from Lig4−/−:Rnf8−/− (B) or Lig4−/−:Rnf168−/− (C) abl pre-B cells expressing non-targeting (shNT) or CtIP (shCtIP) shRNAs using CtIP or GAPDH antibodies. (D, E) Southern blot analysis of XbaI-digested genomic DNA from Lig4−/−:Rnf8−/− or Lig4−/−:Rnf168−/− abl pre-B cells expressing shNT or shCtIP treated with imatinib for the indicated times as described in Fig. 1C. Percentages of intact SEs (iSEs) in imatinib-treated samples are listed below each lane.